JP2022535734A - 縮合複素環誘導体 - Google Patents

縮合複素環誘導体 Download PDF

Info

Publication number
JP2022535734A
JP2022535734A JP2021570274A JP2021570274A JP2022535734A JP 2022535734 A JP2022535734 A JP 2022535734A JP 2021570274 A JP2021570274 A JP 2021570274A JP 2021570274 A JP2021570274 A JP 2021570274A JP 2022535734 A JP2022535734 A JP 2022535734A
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
mmol
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535734A5 (cg-RX-API-DMAC7.html
Inventor
グロッセ,サンドリーヌ,セリーヌ
ディラット,リンジー,グラハム
ファンダイク,コーン
ジャン-マリー バーナード ラボイソン,ピエール
マリア アロイシャス ピーター,セルジュ
ケステレイン,バート,ルドルフ,ロマニー
フェルシュ-レン,ウィム,ガストン
ベルク,ジャン,マーティン
チャールス アール. ルコント,モルガン
ラメンカ,キャロリーナ マルティネス
ヒューゴ マリア ヨンカー,ティム
デン,カン
チャン,イーミン
シュー,ヤンピン
チェン,チャンリン
フ-,リリ-
クデゥク,スコット,ディー
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022535734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022535734A publication Critical patent/JP2022535734A/ja
Publication of JP2022535734A5 publication Critical patent/JP2022535734A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021570274A 2019-05-28 2020-05-27 縮合複素環誘導体 Pending JP2022535734A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
US62/853,533 2019-05-28
EP19176933.0 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20
CNPCT/CN2020/085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (2)

Publication Number Publication Date
JP2022535734A true JP2022535734A (ja) 2022-08-10
JP2022535734A5 JP2022535734A5 (cg-RX-API-DMAC7.html) 2023-06-05

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570274A Pending JP2022535734A (ja) 2019-05-28 2020-05-27 縮合複素環誘導体

Country Status (19)

Country Link
EP (1) EP3976617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022535734A (cg-RX-API-DMAC7.html)
KR (1) KR20220012913A (cg-RX-API-DMAC7.html)
CN (1) CN113906028A (cg-RX-API-DMAC7.html)
AU (1) AU2020285718A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022889A8 (cg-RX-API-DMAC7.html)
CA (1) CA3138168A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016433A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210666A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000230A (cg-RX-API-DMAC7.html)
IL (1) IL288322A (cg-RX-API-DMAC7.html)
JO (1) JOP20210313A1 (cg-RX-API-DMAC7.html)
MA (1) MA56043A (cg-RX-API-DMAC7.html)
MX (1) MX2021014575A (cg-RX-API-DMAC7.html)
PE (1) PE20220767A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552974A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113167QA (cg-RX-API-DMAC7.html)
WO (1) WO2020243135A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
TW202237617A (zh) * 2020-12-02 2022-10-01 愛爾蘭商健生科學愛爾蘭無限公司 稠合雜環衍生物
AR126049A1 (es) 2021-06-02 2023-09-06 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
CA3218641A1 (en) * 2021-06-02 2022-12-08 Chunliang Lu Fused heterocyclic derivatives
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038045A1 (en) * 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
WO2018005881A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
WO2018005883A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
WO2020221826A1 (en) * 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038045A1 (en) * 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
WO2018005881A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
WO2018005883A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
WO2020221826A1 (en) * 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
EP3976617B1 (en) 2025-04-23
JOP20210313A1 (ar) 2021-11-25
CL2021003155A1 (es) 2022-07-22
MA56043A (fr) 2022-04-06
MX2021014575A (es) 2022-05-24
WO2020243135A1 (en) 2020-12-03
PH12021552974A1 (en) 2022-07-11
AU2020285718A1 (en) 2022-02-03
CR20210666A (es) 2022-03-11
PE20220767A1 (es) 2022-05-16
EP3976617A1 (en) 2022-04-06
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
DOP2021000230A (es) 2022-05-31
KR20220012913A (ko) 2022-02-04
SG11202113167QA (en) 2021-12-30
CN113906028A (zh) 2022-01-07
BR112021022889A2 (pt) 2022-01-04
CA3138168A1 (en) 2020-12-03
IL288322A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
KR102319857B1 (ko) P2x7 조절제
EP3976617B1 (en) Fused heterocyclic derivatives
US20210252014A1 (en) Oxadiazepinone derivatives and methods of treating hepatitis b infections
KR20180022818A (ko) 환화 술파모일아릴아미드 유도체 및 b형 간염 치료용 약제로서의 이의 용도
TW202313008A (zh) 稠合雜環衍生物(一)
US20220348592A1 (en) Fused heterocyclic derivatives
JP2022534960A (ja) カプシド集合修飾因子としてのジアゼピノン誘導体
JP2022535216A (ja) カプシド集合修飾因子としての縮合複素環誘導体
JP2022535208A (ja) 抗ウイルス剤としての縮合ヘテロ環誘導体
JP2022534495A (ja) 融合複素環式誘導体
EA047929B1 (ru) Сочлененные гетероциклические производные
HK40066700A (zh) 稠合杂环衍生物
US20240287070A1 (en) Fused heterocyclic derivatives
JP2022534247A (ja) Hbvカプシド集合体モジュレーターとしてのジフルオロアゼパン

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729